Familial Hypercholesterolemia Market Insight and Market Forecast

Familial hypercholesterolaemia (FH), is an autosomal dominant genetic disorder being characterized by the severe hypercholesterolaemia along with cholesterol deposits in tendons and premature heart disease. FH further classified into two homozygous and heterozygous forms.

The estimated overall US prevalence of probable/definite FH was 0.40% or 1 in 250. FH prevalence in the US is varied by age, being least common in 20 to 29-year-olds and most common in 60 to 69-year-olds.[Sarah D. de Ferranti et al. (2016)]
The lowest incident population of FH was recorded in Japan (in 7MM)
United States has the highest percentage of incident diagnosed & treated patients in 7MM
Spain has consistently shown lowest diagnosed & treated population among EU5 Countries
Among the FH patients, females show higher proportion of incidence of FH as compared to males in the 7MM
According to the estimates provided by the National Institute for Health and Clinical Excellence, the reported prevalence of heterozygous familial hypercholesterolaemia in the UK population is estimated to be 1 in 500.

For more details visit:
https://www.delveinsight.com/report-store/Familial%20Hypercholesterolemia%20-%20Market%20Insight